<DOC>
	<DOCNO>NCT00567580</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Androgens cause growth prostate cancer cell . Antihormone therapy , flutamide , bicalutamide , luteinizing hormone-releasing hormone agonist , may lessen amount androgen make body . It yet know regimen radiation therapy without androgen-deprivation therapy effective prostate cancer . PURPOSE : This randomized phase III trial study prostate radiation therapy see well work compare short-term androgen deprivation therapy give together pelvic lymph node radiation therapy without prostate radiation therapy treat patient rise PSA surgery prostate cancer .</brief_summary>
	<brief_title>Prostate Radiation Therapy Short-Term Androgen Deprivation Therapy Pelvic Lymph Node Radiation Therapy With Without Prostate Radiation Therapy Treating Patients With Rising Prostate Specific Antigen ( PSA ) After Surgery Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether addition short-term androgen deprivation ( STAD ) prostate bed radiotherapy ( PBRT ) improve freedom progression ( FFP ) ( i.e. , maintenance prostate-specific antigen [ PSA ] less nadir+2 ng/mL , absence clinical failure , absence death cause ) 5 year , PBRT alone men treat salvage radiotherapy radical prostatectomy . - To determine whether STAD , pelvic lymph node radiotherapy ( PLNRT ) , PBRT improve FFP STAD+PBRT PBRT alone men treat salvage radiotherapy radical prostatectomy . Secondary - To compare rate PSA ≥ 0.4 ng/mL rise 5 year randomization ( secondary biochemical failure endpoint ) , development hormone-refractory disease ( 3 rise PSA treatment salvage androgen-deprivation therapy ) , distant metastasis , cause-specific mortality , overall mortality . - To compare acute late morbidity base Common Toxicity Criteria Adverse Effects ( CTCAE ) , v. 3.0 . - To measure expression cell kinetic , apoptotic pathway , angiogenesis-related gene archival diagnostic tissue well define risk FFP , distant failure , cause-specific mortality , overall mortality salvage radiotherapy prostate cancer , independently conventional clinical parameter use . - To quantify blood product-based proteomic genomic ( single nucleotide polymorphism ) pattern urine-based genomic pattern different time treatment well define risk FFP , distant failure , cause-specific mortality , overall mortality salvage radiotherapy prostate cancer , independently conventional clinical parameter use . - To assess degree , duration , significant difference disease-specific health-related quality life ( HRQOL ) decrements among treatment arm . - To assess whether mood improve depression decrease aggressive therapy improve FFP . - To collect paraffin-embedded tissue block , serum , plasma , urine , buffy coat cell future translational research analysis . Tertiary - To assess whether incremental gain FFP survival aggressive therapy outweigh decrement primary generic domain HRQOL ( i.e. , mobility , self care , usual activity , pain/discomfort , anxiety/depression ) . - To evaluate cost-utility treatment arm demonstrating significant benefit ( term primary outcome ) comparison widely accept cancer non-cancer therapy . - To assess association serum level beta-amyloid measure cognition mood depression . - An exploratory aim ass relationship ( ) American Urological Association Symptom Index ( AUA SI ) urinary morbidity use CTCAE v. 3.0 grading system . OUTLINE : Patients stratify accord seminal vesicle involvement ( yes v ) , prostatectomy Gleason score ( ≤ 7 vs 8-9 ) , pre-radiotherapy PSA ( ≥ 0.1 ≤ 1.0 ng/mL v &gt; 1.0 &lt; 2.0 ng/mL ) , pathology stage ( pT2 margin negative v others ) . Patients randomize 1 3 treatment arm . - Arm I ( prostate bed radiotherapy [ PBRT ] alone ) : Patients undergo PBRT daily , 5 day week , Monday Friday , approximately 7-8 week ( 36 39 fraction ) . - Arm II ( PBRT short-term androgen-deprivation [ STAD ] ) : Beginning 2 month start PBRT , patient undergo STAD , use combination antiandrogen luteinizing hormone-releasing hormone ( LHRH ) agonist therapy , total 4-6 month . Patients receive antiandrogen therapy comprise either oral flutamide 3 time daily oral bicalutamide daily least 4 month ( start within 1-14 day prior LHRH agonist end last day radiotherapy ± 14 day ) . Patients receive LHRH agonist injection begin concurrently 2 week start antiandrogen therapy . LHRH agonist injection consist analog approve FDA ( Health Canada Canadian institution ) ( e.g. , leuprolide , goserelin , buserelin , triptorelin ) may give possible combination ( may give single 4-month injection one two 1-month injection [ ] , two 3-month injection , 6-month injection ) , total LHRH agonist treatment time 4-6 month . Approximately 2 month begin STAD , patient undergo PBRT arm I . - Arm III ( Pelvic lymph node radiotherapy [ PLNRT ] , PBRT , STAD ) : Beginning 2 month start radiotherapy , patient receive STAD therapy arm II . Approximately 2 month begin STAD , patient undergo PBRT PLNRT daily , 5 day week , Monday Friday , approximately 5 week ( 25 fraction ) follow PBRT daily , 5 day week approximately 2-3 week ( 11-14 fraction ) . Patients complete American Urological Association Symptom Index ( AUA SI ) questionnaire prior protocol treatment , week 6 radiotherapy , periodically completion study therapy . After completion study therapy , patient follow every 3 month 1 year , every 6 month 4 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Adenocarcinoma prostate treat primarily radical prostatectomy Pathologically proven lymph nodenegative pelvic lymphadenectomy ( N0 ) lymph node status pathologically unknown ( Nx [ undissected pelvic lymph node lymph node dissection require ] ) Any type radical prostatectomy allow , include retropubic , perineal , laparoscopic , robotically assist Meets 1 follow pathologic classification : T3 N0/Nx disease without positive prostatectomy margin T2 N0/Nx disease without positive prostatectomy margin N1 patient ineligible , pelvic lymph node enlargement ≥ 1.5 cm great dimension CT scan MRI pelvis , unless enlarge lymph node negative Prostatectomy Gleason score 9 less A postradical prostatectomy entry PSA ≥ 0.1 ≤ 1.0 ng/mL least 6 week prostatectomy within 30 day registration Serum total testosterone ≥ 40 % low limit normal ( patient unilateral orchiectomy eligible long requirement meet ) No distant metastasis base history/physical examination , CT scan MRI abdomen pelvis , bone scan No palpable prostatic fossa abnormality/mass suggestive recurrence , unless show biopsy ultrasound guidance contain cancer PATIENT CHARACTERISTICS : Zubrod performance status 01 Platelets ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL ( use transfusion intervention achieve allow ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2 x upper limit normal No prior invasive malignancy ( except nonmelanoma skin cancer ) superficial bladder cancer unless disease free minimum 5 year ( e.g. , carcinoma situ oral cavity permissible ) No severe , active comorbidity , include follow : History inflammatory bowel disease History hepatitis B C Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Hepatic insufficiency result clinical jaundice and/or coagulation defect Acquired immune deficiency syndrome ( AIDS ) base upon current Centers Disease Control ( CDC ) definition HIV testing require entry No prior allergic reaction study drug ( ) involve protocol PRIOR CONCURRENT THERAPY : See Disease Characteristics More 5 year since prior chemotherapy disease site No androgendeprivation therapy start prior prostatectomy &gt; 6 month duration The use finasteride dutasteride ( ± tamsulosin ) long period prior prostatectomy acceptable No androgendeprivation therapy start prostatectomy prior registration The use finasteride dutasteride ( ± tamsulosin ) prostatectomy acceptable , must stop within 3 month prostatectomy No neoadjuvant chemotherapy prostatectomy No prior cryosurgery brachytherapy prostate ( prostatectomy primary treatment salvage procedure ) No prior pelvic radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>